A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia - Trial NCT05886491
Access comprehensive clinical trial information for NCT05886491 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Takeda and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 53 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Takeda
Timeline & Enrollment
Phase 1/2
Jul 07, 2023
Jun 30, 2027
Primary Outcome
Number of Participants With Dose Limiting Toxicities (DLTs),Maximum Tolerated Dose (MTD) of GDX012,Number of Participants With Adverse Events (AEs)
Summary
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer,
 including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe
 GDX012 is, how treatment with GDX012 is tolerated and to determine the best dose of GDX012.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05886491
Non-Device Trial